A Midtown-based medical device startup is carving a niche in the growing field of treatments to address chronic lung disease.
News Medical on MSN13d
Study finds no clinical advantage of budesonide inhaler over fluticasone in COPDA study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...
AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...
But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback